SBMF.F Aperçu des actions Sino Biopharmaceutical Limited, une société holding d'investissement, est un conglomérat pharmaceutique de recherche et de développement en République populaire de Chine. Plus de détails
Récompenses Analyse des risques Voir tous les contrôles de risques Saisissez vos pensées, vos liens et l'histoire de votre entreprise
Sino Biopharmaceutical Limited Concurrents Historique des prix et performances
Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Sino Biopharmaceutical Historique des cours de bourse Prix actuel de l'action HK$0.41 Plus haut sur 52 semaines HK$0.47 Plus bas sur 52 semaines HK$0.31 Bêta 0.68 Variation sur 1 mois -3.00% Variation sur 3 mois n/a Variation sur 1 an n/a Variation sur 3 ans -44.59% Variation sur 5 ans -72.21% Évolution depuis l'introduction en bourse 11.16%
Nouvelles et mises à jour récentes
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection in Combination with Chemotherapy Dec 27
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21 Voir plus de mises à jour
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection in Combination with Chemotherapy Dec 27
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21
Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States Nov 14
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Oct 21
Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO Sep 27
Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024 Sep 16
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma Aug 28
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma Aug 01
Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024 Jul 31
Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule Jul 18
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Jul 16
Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet Jul 15
Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection Jun 25
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)" Jun 19 Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection
Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director Jun 06
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma May 24
Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China May 10
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules May 01
Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024 Mar 29
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024 Mar 28
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225" Mar 16
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet Mar 13
Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 02
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart Feb 28
Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion. Feb 08
Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553) Jan 23
Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain Dec 28
Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma Dec 22
Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722 Dec 12
Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038 Dec 05
An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million. Nov 10
Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug Oct 17
An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million. Oct 12
An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million. Oct 11
Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA Sep 26
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023 Aug 26
Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023 Aug 03
Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms Jul 01
Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine May 24
Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection) May 11
Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation Feb 11
Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer Jan 14
Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203" Dec 10 Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022 Aug 24
Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022 Aug 12 Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022
Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule Jun 28
Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial Jun 15
Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor Innovative Drug "TQ-B3139" May 24
Sino Biopharmaceutical Limited's Category I Anti-Tumor Innovative Drug "TQB2930" Obtained Approval for Clinical Trial Apr 21
Sino Biopharmaceutical Limited Announces Anlotinib Hydrochloride Capsules Obtains Approval for the Fifth Indication Apr 20
Sino Biopharmaceutical Limited Announces Innovative Drug "TQ-B3525" Was Included in the List of Breakthrough Therapy Drugs by CDE Apr 09
Sino Biopharmaceutical Limited Announces That Application for Clinical Trial of "TQC2938" Injection, A Category I New Drug Self-Developed by the Group, Has Been Submitted to and Accepted by the National Medical Products Administration of China Apr 08 Sino Biopharmaceutical Limited, Annual General Meeting, Jun 06, 2022
Sino Biopharmaceutical Limited Announces Category I Anti-Tumour Innovative Medicine FHND5071 Obtained Approval for Clinical Trial Mar 30
Sino Biopharmaceutical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022 Mar 03
Sino Biopharmaceutical Limited Announces Approval of "Adalimumab Solution for Injection" for Marketing Jan 22
Sino Biopharmaceutical Limited Announces Sitagliptin Phosphate and Metformin Hydrochloride Sustained-Release Tablets Obtained Drug Registration Certificate Granted by National Medical Products Administration Jan 12
Sino Biopharmaceutical Limited's TCR1672 Obtains Approval for Clinical Trial Dec 22
Akeso, Inc. and Sino Biopharmaceutical Limited Announces Penpulimab Monoclonal Antibody Marketing Approval in China Aug 08
Sino Biopharmaceutical Limited Announces "Dexmedetomidine Hydrochloride Injection" Obtains Drug Registration Certificate Jul 16
Sino Biopharmaceutical Limited Announces That the Phase Iii Clinical Trial Results of "Anlotinib Hydrochloride Capsules Jun 09
Sino Biopharmaceutical Limited Announces "Tolvaptan Tablets" Obtains Drug Registration Certificate Jun 02
Sino Biopharmaceutical Limited Announces "Sunitinib Malate Capsules" Obtains Drug Registration Certificate May 29 Sino Biopharmaceutical Limited Declares Dividend for the Three Months Ended 31 March, 2021, Payable on 12 July, 2021
Sino Biopharmaceutical Limited Announces "Decitabine for Injection" Passes Consistency Evaluation Mar 14
Sino Biopharmaceutical Limited Announces That the "Fosaprepitant Dimeglumine for Injection", A Drug Developed by the Group Used for the Prevention of Nausea and Vomiting Caused by Chemotherapy, Has Obtained Approval of Abbreviated New Drug Application from the United States Food and Drug Administration Mar 10
Sino Biopharmaceutical Limited to Report Fiscal Year 2020 Results on Mar 23, 2021 Mar 02 Akeso, Inc. and Sino Biopharmaceutical Limited Announce the Interim Analysis of the Phase III Clinical Trial of Penpulimab
Sino Biopharmaceutical Limited Announces Alfacalcidol Soft Capsule Obtains the Notice of Approval of Supplemental Application on Pharmaceutical Product Issued by the National Medical Products Administration of the People's Republic of China Feb 11 Sino Biopharmaceutical Limited Announces "Esomeprazole Magnesium Enteric-Coated Capsules" Obtains Drug Registration Certificate
Sino Biopharmaceutical Limited Announces Passing of Consistency Evaluation for Bortezomib for Injection Jan 24
Akeso, Inc. and Sino Biopharmaceutical Limited Announces Latest Study of Penpulimab Monoclonal Antibody (PD-1) in Combination with Anlotinib for 1L Advanced Hepatocellular Carcinoma Jan 22
Sino Biopharmaceutical Limited Announces Passing of Consistency Evaluation for "Linezolid and Glucose Injection" Jan 09 Sino Biopharmaceutical Limited Obtains Drug Registration Certificate for Afatinib Dimaleate Tablets
Sino Biopharmaceutical Limited Appoints Li Kwok Tung Donald as an Independent Non-Executive Director and a Member of the Audit Committee and Nomination Committee Jan 01
Sino Biopharmaceutical Limited's Digestive System Medicine Pantoprazole Sodium for Injection Obtains the Notice of Approval of Supplemental Applications Issued by the National Medical Products Administration of the People's Republic of China Dec 03
Sino Biopharmaceutical Limited Announces Pomalidomide Capsules Obtains Drug Registration Certificate Nov 14
Sino Biopharmaceutical Limited to Report Q3, 2020 Results on Nov 30, 2020 Nov 03 Sino Biopharmaceutical Limited Announces Completion of Enrollment in Phase Iii Clinical Trial in Combination with Chemotherapy for 1L Metastatic Squamous Nsclc with Penpulimab
Sino Biopharmaceutical Limited Announces Management Changes Aug 22
Sino Biopharmaceutical Limited to Report First Half, 2020 Results on Aug 28, 2020 Aug 04 Rendement pour les actionnaires SBMF.F US Pharmaceuticals US Marché 7D 0% 0.2% -0.5% 1Y n/a 2.0% 23.2%
Voir le rapport complet des actionnaires
Rendement vs Industrie: Données insuffisantes pour déterminer la performance de SBMF.F par rapport au secteur US Pharmaceuticals.
Rendement vs marché: Données insuffisantes pour déterminer la performance de SBMF.F par rapport au marché US.
Volatilité des prix Is SBMF.F's price volatile compared to industry and market? SBMF.F volatility SBMF.F Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 10.9% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.2%
Cours de l'action stable: Le cours de l'action de SBMF.F a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de SBMF.F au cours de l'année écoulée.
À propos de l'entreprise Sino Biopharmaceutical Limited, une société holding d'investissement, est un conglomérat pharmaceutique de recherche et de développement en République populaire de Chine. Ses activités s'articulent autour de trois segments, à savoir les médicaments chinois modernisés et les médicaments chimiques, les investissements et les autres : Médicaments chinois modernisés et médicaments chimiques, Investissements et Autres. La société propose des médicaments oncologiques, notamment des capsules de chlorhydrate d'anlotinib sous la marque Focus V, des injections de penpulimab sous la marque Annike, des injections d'efbemalenograstin alfa sous la marque Yilishu, des capsules de pomalidomide sous la marque Anyue, des injections de bevacizumab sous la marque Anbeisi, des injections de rituximab sous la marque Delituo, et des injections de trastuzumab sous la marque Saituo ; des médicaments contre les maladies du foie, tels que l'isoglycyrrhizinate de magnésium injectable sous la marque Tianqing Ganmei et les comprimés dispersibles d'entécavir sous la marque Runzhong ; et des médicaments pour le système respiratoire comprenant la suspension de budésonide pour inhalation sous la marque Tianqing Suchang et le colistiméthate sodique pour injection sous la marque Tianyun.
Afficher plus Sino Biopharmaceutical Limited Résumé des fondamentaux Comment les bénéfices et les revenus de Sino Biopharmaceutical se comparent-ils à sa capitalisation boursière ? SBMF.F statistiques fondamentales Capitalisation boursière US$6.69b Bénéfices(TTM) US$292.17m Recettes(TTM ) US$3.79b
Bénéfices et recettes Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM) SBMF.F compte de résultat (TTM ) Recettes CN¥27.79b Coût des recettes CN¥5.23b Marge brute CN¥22.56b Autres dépenses CN¥20.41b Les revenus CN¥2.14b
Derniers bénéfices déclarés
Jun 30, 2024
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) 0.12 Marge brute 81.16% Marge bénéficiaire nette 7.71% Ratio dettes/capitaux propres 22.6%
Quelles ont été les performances à long terme de SBMF.F?
Voir les performances historiques et les comparaisons Dividendes
2.0% Rendement actuel des dividendes
Analyse de l'entreprise et données financières Données Dernière mise à jour (heure UTC) Analyse de l'entreprise 2025/01/10 02:19 Cours de l'action en fin de journée 2024/12/19 00:00 Les revenus 2024/06/30 Revenus annuels 2023/12/31
Sources de données Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC . Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
Paquet Données Cadre temporel Exemple de source américaine * Finances de l'entreprise 10 ans Compte de résultat Tableau des flux de trésorerie Bilan Estimations consensuelles des analystes +3 ans Prévisions financières Objectifs de prix des analystes Prix du marché 30 ans Cours des actions Dividendes, scissions et actions Propriété 10 ans Actionnaires principaux Délits d'initiés Gestion 10 ans L'équipe dirigeante Conseil d'administration Principaux développements 10 ans
* exemple pour les titres américains, pour les titres non-américains des formulaires et sources réglementaires équivalents sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). Pour en savoir plus , cliquez ici .
Modèle d'analyse et flocon de neige Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github . Nous avons également des guides sur la façon d'utiliser nos rapports et des tutoriels sur Youtube .
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur .
Sources des analystes Sino Biopharmaceutical Limited est couverte par 51 analystes. 23 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
Analyste Institution Justin Liu BNP Paribas Securities (Asia) Ling Zhang BNP Paribas Securities (Asia) Wai Chak Yuen BOCI Research Ltd.
Afficher 48 plus d'analystes 
